Global Myeloid Leukemia Treatment Market – Industry Trends and Forecast to 2030

Myeloid Leukemia Treatment Market Analysis and Size

Myeloid leukemia (AML) treatment is constantly emerging to cope with the increase in blood cancer cases. Among the several types of leukemia, acute lymphoblastic leukemia (ALL) is often observed in children and young adults, primarily in the age group of 2 to 5 years old; though, myeloid leukemia treatment (AML) is more frequently seen in adults. Leukaemia incidences vary among patients of varied sexes, ages and races and these disparities are associated mainly with levels of environmental exposure as also genetic factors. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the myeloid leukemia treatment market in the forecast period 2023-2030. The market is expected to reach USD 34.30 billion by 2030, which is USD 16 billion in 2022, and is expected to undergo a CAGR of 10% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Myeloid Leukemia Treatment Market Scope and Segmentation

Market Definition

Myeloid leukemia is a kind of cancer of that affects blood and bone marrow. Growing diagnoses of myeloid leukemia which is caused because of exposure to carcinogens which are present everywhere, is leading to increased number of leukemia patients. Symptoms include easy bruising, breathlessness, fatigue, and bleeding. Higher risk factors such as carcinogens, bold disorders, and genetics increase the market expansion.

Myeloid Leukemia Treatment Market Dynamics

Drivers

• Huge Incidence of Myeloid Leukemia

There were around 61,780 new cases of leukemia and 22,840 mortalities in the U.S. in the year 2019. The number of myeloid leukemia treatment cases was expected at 21,450, in which adults held a major portion of the patient population. The growing incidence and increased death rate in the U.S. and other countries are building the way for increased uptake of associated therapies. It has been witnessed that 44% of acute myeloid leukaemia cases in the U.K. are in females, and 56% are in males. This factor boosts the market growth.

• Increase in Elderly Population

The elderly population is anticipated to increase the patient population worldwide, which boots the market in the forecast period 2023-2030. As per the records of the WHO, the global elderly population is anticipated to reach about 2 billion by 2050 from 617 million in 2015. The possibility of getting infected with several types of cancer also rises in this population. This factor will incease the demand of the treatment processes. This boost the market growth.

Opportunities

• Increase in usage in Hospitals

Hospitals and specialty clinics are the biggest end user of the leukemia treatment market and it is increasing because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for reducing the basal cell carcinoma cases. Thus, this factor will lead the market growth.

• Increased Technological Advancements

Traditional options for this diseased condition are unable to control relapse and are associated with several side-effects such as tissue damage, nausea and loss of appetite. These issues are increasing companies' focus on numerous advanced approaches such as serine-threonine protein kinases, stem cell transplant and pipeline drugs. There are numerous upcoming therapies such as immunotoxins, farnesyltransferase inhibitors, alkylating agents, FMS-like tyrosine kinase 3 inhibitors, monoclonal antibodies and multi-drug-resistant modulators that are going to contribute in the betterment of the patient condition. This creates more opportunity in the market.

Restraints/Challenges

• High Cost of Treatment

The increased expenditure of the treatment methods impede the market growth. Cost is a major factors that impacts the selection of treatment. Therefore, the high cost of myeloid leukemia treatment drugs is projected to hinder the growth of the market. Additionally, in an article published by American Society of Clinical Oncology Journal in 2020, the total annualized costs for CML was around US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S. Thus, this factor hampers the market growth.

This myeloid leukemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the myeloid leukemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, the US FDA granted the company orphan drug designation for its pipeline compound OM-301 designated for the treatment of myeloid leukemia treatment (AML). It is developed by Oncolyze Inc.
• In 2021, the European Commission granted Orphan Drug Designation to SNDX-5613. It is a highly selective oral menin inhibitor for treating patients suffering from myeloid leukemia treatment (AML). It is developed by Syndax Pharmaceuticals Inc.

Global Myeloid Leukemia Treatment Market Scope

The myeloid leukemia treatment market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute myeloid leukemia (AML)
• Chronic myeloid leukemia (CML)
• Others

Treatment Type

• Targeted Therapy
• Chemotherapy
• Cytarabine
• Anthracycline Drugs
• Alkylating Agents
• Anti-metabolites
• Tyrosine Kinase Inhibitors
• Immunotherapy
• Hormone Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Myeloid Leukemia Treatment Market Regional Analysis/Insights

The myeloid leukemia treatment market is analyzed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the myeloid leukemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth because of the focus of major market players on novel technology. The increasing occurrence of acute myeloid leukemia in the U.S. will lead to higher adoption of therapy for this disease, thus anticipated to boost the growth of this market in North America.

Asia-Pacific dominates the market because of the high incidence rates of leukemia. Rising R&D and product launches for myeloid leukemia are further anticipated to drive the market growth in this region. For instance, Bristol Myers Squibb received the US FDA approval for Onureg for the continued treatment of adult patients with acute myeloid leukemia who are not able to complete intensive curative therapy in 2020. ​

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Myeloid Leukemia Treatment Market Share Analysis

The myeloid leukemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to myeloid leukemia treatment market.

Key players operating in the myeloid leukemia treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Cipla Inc. (U.S.
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
•  Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Fresenius Kabi AG (Germany)
• Viracta Therapeutics, Inc. (U.K.)

SKU-52897